NPTX Projected Dividend Yield

Neuropathix Inc ( OTCBB : NPTX )

Neuropathix is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a range of disease areas. Co.'s primary target drug candidate, KLS-13019, is part of an estate of new chemical entities underlying patent titled Functionalized 1,3 Benzene-diols and their Method of Use for the Treatment of Hepatic Encephalopathy (HE). Co.'s product candidates include: KLS-13019, which is for the target indication of chemotherapy induces, peripheral neuropathy, and mild traumatic brain injury; and KLS-13023, which is for the target indication of overt HE and mild traumatic brain injury.

20 YEAR PERFORMANCE RESULTS